You are here
Triplex Pharmaceutical
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: Yes
Woman Owned: No
Award Charts
Award Listing
-
Development of a Novel Anti-HIV Oligonucleotide
Amount: $98,800.00AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haa ...
SBIRPhase I1995Department of Health and Human Services -
Development of a Novel Cytomegalovirus Drug
Amount: $100,000.00Cytomegalovirus (CMV) causes severe infections in infants, organ transplant recipients and AIDS patlong term objective of this work is to treat humans who have cytomegalovirus infections with a novels ...
SBIRPhase I1995Department of Health and Human Services -
Active Anti-HIV Guanosine/Thymidine Oligonucleotides
Amount: $100,000.00We will develop a new class of oligonucleotides, which fold themselves into ordered structures andmainly of deoxyguanosine and deoxythymidine (GTOs), as therapeutic antiviral agents active against HGT ...
SBIRPhase I1995Department of Health and Human Services -
Alkenylguanine Analogs--A New Class of Antiviral Agent
Amount: $100,000.00We will develop certain structure activity relationships with respect to a novel class of antiviralconduct preliminary experiments designed to define the mechanism of action for these drugs. Prelimine ...
SBIRPhase I1995Department of Health and Human Services -
New Delivery Systems for Therapeutic Oligonucleotides
Amount: $100,000.00Antisense and triple helix-forming oligonucleotides (TFOs) have great potential as therapeutic agenspecifically block the expression of deleterious genes. We will develop novel delivery vehicles, toin ...
SBIRPhase I1995Department of Health and Human Services -
Oligonucleotides Inhibition of HIV-1 Integrase
Amount: $65,956.00Effective therapy for human immunodeficiency virus (HIV) infection remains elusive, partly dueto the fact that infected long lived cells provide a reservoir for the virus. Currently availableanti-retr ...
SBIRPhase I1994Department of Health and Human Services -
Enhanced Efficacy of Triplex Oligonucleotides
Amount: $50,000.00We will develop a novel class of therapeutics based on Triple-Helix Forming Oligonucleotides (TFOs). Attachment of lipophilic groups to anti-cancer and anti- HSV-2 TFOs will be examined to enhance the ...
SBIRPhase I1993Department of Health and Human Services -
Triplex Inhibition of Progesterone Receptor
Amount: $50,000.00Triple helix formation between duplex DNA and oligonucleotides has been observed for over twenty years for synthetic polymers and more recently for genomic DNA. Triplex formation prevents the associat ...
SBIRPhase I1993Department of Health and Human Services -
Anti-HCMV Activity of Triple Helix-Forming Oligos
Amount: $40,000.00The aim is to test the feasibility of using triple helix (triplex)-forming oligonucleotides as antiviral agents against human cytomegalovirus. Oligonucleotides have long been known to be capable of bi ...
SBIRPhase I1993Department of Health and Human Services -
MODIFIED NUCLEOSIDES IN TRIPLEX FORMING OLIGONUCLEOTIDES
Amount: $50,000.00THE PRIMARY GOAL OF THIS STUDY IS TO CHEMICALLY REFINE A CLASS OF SEQUENCE-SPECIFIC, DNA BINDING, TRIPLE HELIX-FORMING OLIGONUCLEOTIDES (TFOS). THE UNIQUE FEATURE OF THESE TFOS IS THAT BINDING OF THE ...
SBIRPhase I1992Department of Health and Human Services